Aducanumab (anti-Aβ monoclonal) reduces brain amyloid plaque burden dose- and time-dependently in mild-AD patients (Phase Ib PRIME trial); pilot signal of cognitive benefit at higher doses, with ARIA-E rate APOE4-dose-dependent. The Phase Ib that motivated ENGAGE/EMERGE.

Evidence span

Aducanumab (anti-Aβ monoclonal) reduces brain amyloid plaque burden dose- and time-dependently in mild-AD patients (Phase Ib PRIME trial); pilot signal of cognitive benefit at higher doses, with ARIA-E rate APOE4-dose-dependent. The Phase Ib that motivated ENGAGE/EMERGE.

From Jeff Sevigny et al. 2016, Nature

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, mild AD with PET-confirmed amyloid; aducanumab IV monthly vs placebo; n=165. PRIME (NCT01677572).

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required